Clinical Trial Update: Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer

View source ↗

Summary

A clinical trial evaluating Nexavar (sorafenib) for renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Status: WITHDRAWN